V-maf musculoaponeurotic fibrosarcoma oncogene homolog A synthetic modified mRNA drives reprogramming of human pancreatic duct-derived cells into insulin-secreting cells

Elisa Corritore, Yong Syu Lee, Valentina Pasquale, Daniela Liberati, Mei Ju Hsu, Catherine Anne Lombard, Patrick van der Smissen, Amedeo Vetere, Susan Bonner-Weir, Lorenzo Piemonti, Etienne Sokal, Philippe A. Lysy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

β-Cell replacement therapy represents the most promising approach to restore β-cell mass and glucose homeostasis in patients with type 1 diabetes. Safety and ethical issues associated with pluripotent stem cells stimulated the search for adult progenitor cells with endocrine differentiation capacities. We have already described amodel for expansion and differentiation of human pancreatic duct-derived cells (HDDCs) into insulin-producing cells. Here we show an innovative and robust in vitro system for large-scale production of β-like cells from HDDCs using a nonintegrative RNA based reprogramming technique. Synthetic modified RNAs for pancreatic transcription factors (pancreatic duodenal homeobox 1, neurogenin3, and V-Mafmusculoaponeurotic fibrosarcoma oncogene homolog A [MAFA]) were manufactured and daily transfected in HDDCs without strongly affecting immune response and cell viability. MAFA overexpression was efficient and sufficient to induce β-cell differentiation of HDDCs, which acquired a broad repertoire of mature β-cell markers while downregulating characteristic epithelial-mesenchymal transition markers. Within 7 days, MAFA-reprogrammed HDDC populations contained 37% insulin-positive cells and a proportion of endocrine cells expressing somatostatin and pancreatic polypeptide. Ultrastructure analysis of differentiated HDDCs showed both immature and mature insulin granules with lightbackscattering properties. Furthermore, in vitro HDDC-derived β cells (called β-HDDCs) secreted human insulin and C-peptide in response to glucose, KCl, 3-isobutyl-1-methylxanthine, and tolbutamide stimulation. Transplantation of β-HDDCs into diabetic SCID-beige mice confirmed their functional glucose-responsive insulin secretion and their capacity to mitigate hyperglycemia. Our data describe a new, reliable, and fast procedure in adult human pancreatic cells to generate clinically relevant amounts of new β cells with potential to reverse diabetes.

Original languageEnglish
Pages (from-to)1525-1537
Number of pages13
JournalStem cells translational medicine
Volume5
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Fibrosarcoma
Pancreatic Ducts
Insulin-Secreting Cells
Oncogenes
Messenger RNA
Insulin
Glucose
RNA
Pancreatic Polypeptide
1-Methyl-3-isobutylxanthine
Tolbutamide
Pluripotent Stem Cells
Epithelial-Mesenchymal Transition
Endocrine Cells
SCID Mice
C-Peptide
Homeobox Genes
Cell- and Tissue-Based Therapy
Somatostatin
Type 1 Diabetes Mellitus

Keywords

  • Diabetes
  • Insulin-producing cells
  • SCID-beige mice
  • Synthetic modified mRNA
  • V-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA)

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

V-maf musculoaponeurotic fibrosarcoma oncogene homolog A synthetic modified mRNA drives reprogramming of human pancreatic duct-derived cells into insulin-secreting cells. / Corritore, Elisa; Lee, Yong Syu; Pasquale, Valentina; Liberati, Daniela; Hsu, Mei Ju; Lombard, Catherine Anne; van der Smissen, Patrick; Vetere, Amedeo; Bonner-Weir, Susan; Piemonti, Lorenzo; Sokal, Etienne; Lysy, Philippe A.

In: Stem cells translational medicine, Vol. 5, No. 11, 01.11.2016, p. 1525-1537.

Research output: Contribution to journalArticle

Corritore, E, Lee, YS, Pasquale, V, Liberati, D, Hsu, MJ, Lombard, CA, van der Smissen, P, Vetere, A, Bonner-Weir, S, Piemonti, L, Sokal, E & Lysy, PA 2016, 'V-maf musculoaponeurotic fibrosarcoma oncogene homolog A synthetic modified mRNA drives reprogramming of human pancreatic duct-derived cells into insulin-secreting cells', Stem cells translational medicine, vol. 5, no. 11, pp. 1525-1537. https://doi.org/10.5966/sctm.2015-0318
Corritore, Elisa ; Lee, Yong Syu ; Pasquale, Valentina ; Liberati, Daniela ; Hsu, Mei Ju ; Lombard, Catherine Anne ; van der Smissen, Patrick ; Vetere, Amedeo ; Bonner-Weir, Susan ; Piemonti, Lorenzo ; Sokal, Etienne ; Lysy, Philippe A. / V-maf musculoaponeurotic fibrosarcoma oncogene homolog A synthetic modified mRNA drives reprogramming of human pancreatic duct-derived cells into insulin-secreting cells. In: Stem cells translational medicine. 2016 ; Vol. 5, No. 11. pp. 1525-1537.
@article{11790f172cab4e92a219c34681350ae6,
title = "V-maf musculoaponeurotic fibrosarcoma oncogene homolog A synthetic modified mRNA drives reprogramming of human pancreatic duct-derived cells into insulin-secreting cells",
abstract = "β-Cell replacement therapy represents the most promising approach to restore β-cell mass and glucose homeostasis in patients with type 1 diabetes. Safety and ethical issues associated with pluripotent stem cells stimulated the search for adult progenitor cells with endocrine differentiation capacities. We have already described amodel for expansion and differentiation of human pancreatic duct-derived cells (HDDCs) into insulin-producing cells. Here we show an innovative and robust in vitro system for large-scale production of β-like cells from HDDCs using a nonintegrative RNA based reprogramming technique. Synthetic modified RNAs for pancreatic transcription factors (pancreatic duodenal homeobox 1, neurogenin3, and V-Mafmusculoaponeurotic fibrosarcoma oncogene homolog A [MAFA]) were manufactured and daily transfected in HDDCs without strongly affecting immune response and cell viability. MAFA overexpression was efficient and sufficient to induce β-cell differentiation of HDDCs, which acquired a broad repertoire of mature β-cell markers while downregulating characteristic epithelial-mesenchymal transition markers. Within 7 days, MAFA-reprogrammed HDDC populations contained 37{\%} insulin-positive cells and a proportion of endocrine cells expressing somatostatin and pancreatic polypeptide. Ultrastructure analysis of differentiated HDDCs showed both immature and mature insulin granules with lightbackscattering properties. Furthermore, in vitro HDDC-derived β cells (called β-HDDCs) secreted human insulin and C-peptide in response to glucose, KCl, 3-isobutyl-1-methylxanthine, and tolbutamide stimulation. Transplantation of β-HDDCs into diabetic SCID-beige mice confirmed their functional glucose-responsive insulin secretion and their capacity to mitigate hyperglycemia. Our data describe a new, reliable, and fast procedure in adult human pancreatic cells to generate clinically relevant amounts of new β cells with potential to reverse diabetes.",
keywords = "Diabetes, Insulin-producing cells, SCID-beige mice, Synthetic modified mRNA, V-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA)",
author = "Elisa Corritore and Lee, {Yong Syu} and Valentina Pasquale and Daniela Liberati and Hsu, {Mei Ju} and Lombard, {Catherine Anne} and {van der Smissen}, Patrick and Amedeo Vetere and Susan Bonner-Weir and Lorenzo Piemonti and Etienne Sokal and Lysy, {Philippe A.}",
year = "2016",
month = "11",
day = "1",
doi = "10.5966/sctm.2015-0318",
language = "English",
volume = "5",
pages = "1525--1537",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "11",

}

TY - JOUR

T1 - V-maf musculoaponeurotic fibrosarcoma oncogene homolog A synthetic modified mRNA drives reprogramming of human pancreatic duct-derived cells into insulin-secreting cells

AU - Corritore, Elisa

AU - Lee, Yong Syu

AU - Pasquale, Valentina

AU - Liberati, Daniela

AU - Hsu, Mei Ju

AU - Lombard, Catherine Anne

AU - van der Smissen, Patrick

AU - Vetere, Amedeo

AU - Bonner-Weir, Susan

AU - Piemonti, Lorenzo

AU - Sokal, Etienne

AU - Lysy, Philippe A.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - β-Cell replacement therapy represents the most promising approach to restore β-cell mass and glucose homeostasis in patients with type 1 diabetes. Safety and ethical issues associated with pluripotent stem cells stimulated the search for adult progenitor cells with endocrine differentiation capacities. We have already described amodel for expansion and differentiation of human pancreatic duct-derived cells (HDDCs) into insulin-producing cells. Here we show an innovative and robust in vitro system for large-scale production of β-like cells from HDDCs using a nonintegrative RNA based reprogramming technique. Synthetic modified RNAs for pancreatic transcription factors (pancreatic duodenal homeobox 1, neurogenin3, and V-Mafmusculoaponeurotic fibrosarcoma oncogene homolog A [MAFA]) were manufactured and daily transfected in HDDCs without strongly affecting immune response and cell viability. MAFA overexpression was efficient and sufficient to induce β-cell differentiation of HDDCs, which acquired a broad repertoire of mature β-cell markers while downregulating characteristic epithelial-mesenchymal transition markers. Within 7 days, MAFA-reprogrammed HDDC populations contained 37% insulin-positive cells and a proportion of endocrine cells expressing somatostatin and pancreatic polypeptide. Ultrastructure analysis of differentiated HDDCs showed both immature and mature insulin granules with lightbackscattering properties. Furthermore, in vitro HDDC-derived β cells (called β-HDDCs) secreted human insulin and C-peptide in response to glucose, KCl, 3-isobutyl-1-methylxanthine, and tolbutamide stimulation. Transplantation of β-HDDCs into diabetic SCID-beige mice confirmed their functional glucose-responsive insulin secretion and their capacity to mitigate hyperglycemia. Our data describe a new, reliable, and fast procedure in adult human pancreatic cells to generate clinically relevant amounts of new β cells with potential to reverse diabetes.

AB - β-Cell replacement therapy represents the most promising approach to restore β-cell mass and glucose homeostasis in patients with type 1 diabetes. Safety and ethical issues associated with pluripotent stem cells stimulated the search for adult progenitor cells with endocrine differentiation capacities. We have already described amodel for expansion and differentiation of human pancreatic duct-derived cells (HDDCs) into insulin-producing cells. Here we show an innovative and robust in vitro system for large-scale production of β-like cells from HDDCs using a nonintegrative RNA based reprogramming technique. Synthetic modified RNAs for pancreatic transcription factors (pancreatic duodenal homeobox 1, neurogenin3, and V-Mafmusculoaponeurotic fibrosarcoma oncogene homolog A [MAFA]) were manufactured and daily transfected in HDDCs without strongly affecting immune response and cell viability. MAFA overexpression was efficient and sufficient to induce β-cell differentiation of HDDCs, which acquired a broad repertoire of mature β-cell markers while downregulating characteristic epithelial-mesenchymal transition markers. Within 7 days, MAFA-reprogrammed HDDC populations contained 37% insulin-positive cells and a proportion of endocrine cells expressing somatostatin and pancreatic polypeptide. Ultrastructure analysis of differentiated HDDCs showed both immature and mature insulin granules with lightbackscattering properties. Furthermore, in vitro HDDC-derived β cells (called β-HDDCs) secreted human insulin and C-peptide in response to glucose, KCl, 3-isobutyl-1-methylxanthine, and tolbutamide stimulation. Transplantation of β-HDDCs into diabetic SCID-beige mice confirmed their functional glucose-responsive insulin secretion and their capacity to mitigate hyperglycemia. Our data describe a new, reliable, and fast procedure in adult human pancreatic cells to generate clinically relevant amounts of new β cells with potential to reverse diabetes.

KW - Diabetes

KW - Insulin-producing cells

KW - SCID-beige mice

KW - Synthetic modified mRNA

KW - V-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA)

UR - http://www.scopus.com/inward/record.url?scp=84992080183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992080183&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0318

DO - 10.5966/sctm.2015-0318

M3 - Article

VL - 5

SP - 1525

EP - 1537

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 11

ER -